Home Newsfeeds Liminal Biosciences Q4 2022 Net Loss C$(4.2M)

Liminal Biosciences Q4 2022 Net Loss C$(4.2M)

Liminal Biosciences (NASDAQ:LMNL) will report on Q4 2022.

byBenzinga Newsdesk

March 15, 2023

1 minute read

Liminal Biosciences (NASDAQ:LMNL) will report on Q4 2022.

USD Coin Defies Gravity And Returns To $1 Peg After Nail-Biting Weekend

By Murtuza Merchant

March 13, 10:27 AM

Stablecoin USD Coin (CRYPTO: USDC), issued by Circle, is gradually returning to its $1 peg, after a tumultuous weekend, after CEO Jeremy Allaire

This Analyst Expects Solid October Sales Report From Costco

By Shivani Kumaresan

October 28, 2:11 PM

Telsey Advisory Group analyst Joseph Feldman reiterated an Outperform rating on the shares of Costco Wholesale Corp (NASDAQ:COST) with a price target…

COST

Wells Fargo Maintains Overweight on TransDigm Gr, Raises Price Target to $740

By Benzinga Newsdesk

August 16, 7:42 AM

Wells Fargo analyst Matthew Akers maintains TransDigm Gr (NYSE:TDG) with a Overweight and raises the price target from $620 to $740.

TDG

WeTrade Group Announces Strategic Alliance for Global Social E-commerce and Payment Business

By Charles Gross

October 14, 12:09 PM

WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG) today announced that it has entered into multiple strategic cooperation framework agreements (the "Agreements") with Second Pay Financing Inc.(1), Manny's Money Remittance and Forex Services Inc. (2), Supay Fintech Ltd.

WETG

Liminal Biosciences Q4 2022 Net Loss C$(4.2M)

Related Posts

USD Coin Defies Gravity And Returns To $1 Peg After Nail-Biting Weekend

This Analyst Expects Solid October Sales Report From Costco

Wells Fargo Maintains Overweight on TransDigm Gr, Raises Price Target to $740

WeTrade Group Announces Strategic Alliance for Global Social E-commerce and Payment Business